To evaluate the effect of senolytics on muscle regeneration in an FSHD animal model

Facioscapulohumeral muscular dystrophy (FSHD) is a relatively common progressive muscle disease. Recent research by the team suggests senescence (when cells stop dividing but remain active) and the release of harmful signals called the senescence-associated secretory phenotype (SASP), may play a role in muscle damage in FSHD. This project aims to identify which specific cell types become senescent and contribute to SASP in affected muscles. There is growing evidence that drugs targeting senescent cells, called senolytics, can reduce muscle degeneration and improve muscle repair. This project will explore how senescence contributes to FSHD and test whether senolytics can prevent muscle damage and promote muscle regeneration. If successful, this research will lay the groundwork for senolytic therapies as a potential treatment option to improve quality of life for people living with FSHD.